Amgen to Pay $95 Million to Settle Suit Over Failure to Disclose Aranesp Data

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Amgen Inc. agreed to pay $95 million to settle a class action suit filed by investors who bought the company’s securities between April 2004 and May 2007.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Paul Goldberg
Editor & Publisher
Table of Contents

YOU MAY BE INTERESTED IN

Throughout my career as a physician and scientist, I’ve seen ideas once considered impossible become breakthroughs that save lives. They happened because talented scientists had the resources, institutions, and sustained support to pursue ambitious ideas. Most importantly, they knew patients could not afford to wait. 
Paul Goldberg
Editor & Publisher

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login